Lu Daopei Hospital
AVERAGE CAR-T COST OF TREATMENT: USD80,000
The story of CAR-T therapy in China is inseparably linked with the Lu Daopei Hospital, named after its founder professor Lu Daopei.
Lu Daopei is an outstanding Chinese scientist, a world-famous unique specialist in bone marrow transplantation. Professor Lu was at the forefront of bone marrow transplantation in China and was the first to conduct such operation in Asia in 1964. It took him years of research and clinical experience to become a world-famous scientist.
The Chinese CAR-T cell method has become attractive because it has produced very good efficacy thus far, combined with relative safety. That China or other sites outside the US can be part of such collaborations may be the new reality and, perhaps, the wave of the future. As one of the most active Immunotherapy centers general hematology department of Lu Daopei Hospital has completed more than 470 cases modified second generation CAR-T clinical trials.
The CAR-T clinical trial in Lu Daopei Hospital is for patients with:
B-cell acute lymphoblastic leukemia (B-ALL),
B Cell Lymphoma,
Multiple myeloma (MM),
Acute Myeloid Leukemia (AML),
who developed refractory or relapsed disease from chemotherapy.
CAR-T therapy could help patient into complete remission. CAR-T therapy complete recovery rate is about 90%. And bridging BMT after CAR-T for B-ALL could further increase the potential cure rate.
The president Lu Daopei Hospital, Peihua (Peggy) Lu, is one of the most renowned experts in CAR-T therapy. A doctor with a brilliant education who worked at Stanford University (USA) for many years, Dr. Lu conducts a series of studies aimed at expanding the list of diagnoses for which this type of therapy can be used.
The research laboratory is located on the territory of hospital, that helps specialists quickly modify existing treatment protocols individually for each patient. The hospital's specialists were able to improve the technology by combining CAR-T with allogeneic hematopoietic stem cell transplantation, which significantly reduces the risk of relapse and further improves the prognosis.
Lu Daopei Hospital is specialized in leukemia, myeloma, lymphomas and malignant anemia and achieves quick results. Blood cancers are the only indication for the use of CAR-T therapy.